Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort
Segura, Alex G. (Universitat de Barcelona)
Mané, Anna (Institut Hospital del Mar d'Investigacions Mèdiques)
Prohens, Llucia (Universitat de Barcelona)
Rodriguez, Natalia (Universitat de Barcelona)
Mezquida, Gisela (Hospital Clínic i Provincial de Barcelona)
Cuesta, Manuel J. (Instituto de Investigación Sanitaria de Navarra)
Vieta, Eduard (Universitat de Barcelona)
Amoretti, Silvia (Hospital Universitari Vall d'Hebron)
Lobo, Antonio (Instituto de Investigación Sanitaria de Aragón)
González-Pinto, Ana (Universidad del País Vasco)
Díaz-Caneja, Covadonga M. (Universidad Complutense de Madrid)
Roldan-Bejarano, Alexandra (Institut d'Investigació Biomèdica Sant Pau)
Jimenez, Esther (Universitat de Barcelona)
Ponsa Arjona, Immaculada (Hospital Clínic i Provincial de Barcelona)
Legido, Teresa (Institut Hospital del Mar d'Investigacions Mèdiques)
Saiz-Ruiz, Jerónimo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid))
Bernardo, Miquel (Hospital Clínic i Provincial de Barcelona)
Mas, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRS) and cannabis use disorder (PRS) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRS reported increased baseline cannabis use. PRS was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.
Grants:	Ministerio de Ciencia e Innovación PI11/00325 Ministerio de Economía y Competitividad PI14/00612 Instituto de Salud Carlos III PI20/00661
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cannabis ; Genetics ; Polygenic risk score ; Psychosis ; Schizophrenia
Published in:	Psychiatry research, Vol. 325 (july 2023) , p. 115249, ISSN 1872-7123

DOI: 10.1016/j.psychres.2023.115249
PMID: 37178502

7 p, 476.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles